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Abstract c-Jun NH2-terminal kinase (JNK) has been shown to
negatively regulate insulin signaling through serine phosphory-
lation of residue 307 within the insulin receptor substrate-1
(IRS-1) in adipose and liver tissue. Using a rat hindlimb sus-
pension model for muscle disuse atrophy, we found that JNK
activity was signi¢cantly elevated in atrophic soleus muscle and
that IRS-1 was phosphorylated on Ser307 prior to the degrada-
tion of the IRS-1 protein. Moreover, we observed a correspond-
ing reduction in Akt activity, providing biochemical evidence for
the development of insulin resistance in atrophic skeletal muscle.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Skeletal muscle atrophy is a consequence of prolonged
muscle disuse from limb immobilization, extended bed rest,
space £ight or other factors [1]. Muscle unloading has been
shown to primarily a¡ect slow-twitch, anti-gravity muscles
such as the soleus and adductor longus, resulting in muscle
wasting, increased fatigue, and decreased contractile function
(reviewed in [2]). Decreased protein synthesis [3] and increased
protein degradation [4,5] are believed to contribute to the
overall loss in skeletal muscle protein. Numerous metabolic
alterations are associated with the development of atrophy,
including an increased expression of fast-type myosin heavy
chain (MHC) with the selective loss of the slow-type MHC [6^
10], and a diminished ability to oxidize fatty acids [11] with an
enhanced dependence upon carbohydrates as a fuel source
[11,12]. Finally, the development of atrophy is accompanied
by an increase in insulin resistance in the slow-twitch muscles
[13^16] by a mechanism that is poorly understood.
The c-jun NH2-terminal kinase (JNK) members of the
MAP kinase family are part of a phosphorylation cascade
that phosphorylate both nuclear and non-nuclear proteins in
response to cellular stress signals [17]. In skeletal muscle, JNK
is activated during stretch, exercise, and contraction [18^20],
although the physiological signi¢cance of JNK activation in
muscle function is unknown. Recent studies have implicated
JNK-dependent serine phosphorylation of the insulin receptor
substrate-1 (IRS-1) in negative regulation of the insulin recep-
tor. The phosphorylation of IRS-1 Ser307 occurs in response
to cytokines, metabolites, cell stress, or chronic insulin stim-
ulation [21^29], in both JNK-dependent and -independent
manners. Ser307 phosphorylation of IRS-1 prevents associa-
tion of its protein tyrosine binding domain with the insulin
receptor L-subunit, thereby preventing IRS-1 binding to the
receptor and the insulin-dependent activation of PI 3-kinase
[23]. Additionally, Ser307 phosphorylation of IRS-1 following
chronic insulin stimulation has been shown to lead to its
ubiquitin-proteasome-mediated degradation [28,30,31]. Fi-
nally, obese mice display elevated JNK levels in adipose, liver,
and muscle tissue; similar mice in a JNK13=3 background
(but not JNK23=3) have lower Ser307 IRS-1 and circulating
insulin and plasma glucose [26], indicating that JNK1 may be
a novel therapeutic target for obesity and type 2 diabetes.
In this study, we used a rat hindlimb suspension model for
skeletal muscle disuse atrophy, and examined the role of JNK
with respect to insulin resistance. We observed an atrophy-
dependent increase in JNK activity and IRS-1 Ser307 phos-
phorylation. Therefore, similar to obesity-induced insulin re-
sistance, JNK activation during atrophy may be a negative
regulator of insulin signaling and provide a target for anti-
atrophy therapeutics.
2. Materials and methods
2.1. Materials
Antibodies directed against IRS-1, IRS-2, and phospho-IRS-1
(Ser307) were purchased from Upstate Biotechnology (Lake Placid,
NY, USA). Antibodies against Akt, phospho-Akt (Ser473), phospho-
p38 (Thr183/Tyr185), JNK1/2, and phospho-JNK (Thr183/Tyr185), gly-
cogen synthase kinase-3L (GSK-3L), and phospho-GSK-3L (Ser9)
were purchased from Cell Signaling Technology (Beverly, MA,
USA). The glucose transporter-4 (GLUT4) antibody was from Chem-
icon (Temecula, CA, USA). The insulin receptor L-subunit antibody
was from PharMingen (San Diego, CA, USA). Erk 1/2, phospho-Erk
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(Tyr204), p38, and all secondary antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
2.2. Rat hindlimb suspension
Female, virgin Sprague^Dawley derived albino rats were received
from Simonsen Laboratories (Gilroy, CA, USA). Upon receipt, ani-
mals were individually housed in National Aeronautics and Space
Administration (NASA) designed HLS/metabolic cages. Animals
were kept in a room maintained at 22N2‡C with a 12:12 h light/
dark cycle. The rats were fed certi¢ed rodent chow (TD 8728C, Har-
lan Teklad, Madison, WI, USA) in powder form to prevent contam-
ination of urine during the study’s metabolic collection periods. Chow
and water were provided ad libitum throughout the study.
Prior to the study, female rats were acclimated for 7 days. Female
rats, age 77 days, were given a number, then randomly assigned
(n=10/group) so that initial body mass between the di¡erent treat-
ment groups did not di¡er. Animals were kept as ambulatory (AMB)
controls or subjected to hindlimb suspension (HLS) according to the
Morey^Holton procedure [32]. For this procedure, the tails of rats are
lightly attached to a swivel on the top of the cage, providing a 30‡
head-down tilt. The swivel moves in a 360‡ angle and is attached to a
set a bearings on an x^y plane, allowing for full access to food and
water. At no point during the suspension are the hind limbs allowed
to contact the surface of the cage. An experimental period of 38 days
was selected to examine the e¡ect of chronic exposure to HLS; at the
end of the study, the rats were anesthetized with iso£urane, bled by
cardiac puncture then decapitated. Following excision and weighing,
the gastrocnemius (gastroc) and soleus were then frozen in liquid
nitrogen. All procedures used in this study conformed to the National
Research Council guide for use and care of laboratory animals. The
animal protocol for this study was approved by the IACUC.
2.3. In vitro JNK assay
Three gastroc and soleus muscles from AMB and HLS rats were
snap-frozen in liquid nitrogen, and crushed into a powder with a
mortar and pestle. The powder was lysed on ice in modi¢ed RIPA
bu¡er (20 mM Tris, pH 7.4, 137 mM NaCl, 10% glycerol, 0.5%
deoxycholate, 1.0% NP-40, 10 mM EDTA, 10 mM EGTA, 250 WM
PMSF, 5 Wg/ml leupeptin, 200 WM sodium vanadate, 0.01 WM micro-
cystin). From each lysate, 0.375 mg of protein was tumbled with GST-
c-jun coupled to glutathione Sepharose 4B beads for 1 h at 4‡C. The
bead complexes were washed twice in modi¢ed RIPA and once in
MOPS bu¡er (20 mM MOPS, pH 7.2, 2 mM EGTA, 10 mM MgCl2,
1 mM dithiothreitol (DTT), 0.1% Triton X-100). Kinase assays were
performed at 30‡C for 20 min in 50 Wl assay bu¡er (16 mM MOPS,
pH 7.2, 1.6 mM EGTA, 0.8 mM DTT, 0.08% Triton X-100, 10 mM
MgCl2, 0.5 mM ATP, 0.4 mCi/ml [Q-32P]ATP). Reactions were termi-
nated in sodium dodecyl sulfate (SDS) sample bu¡er with boiling and
separated on a 12% SDS^PAGE gel. Following drying, the gel was
exposed to ¢lm for 2 h and developed. GST-c-jun bands were then
excised from the dried gel and counted. Results are reported as the
average of three experiments performed in duplicate N standard error
of the mean. Signi¢cance was determined by two-factor ANOVA with
replication.
2.4. Immunoblotting
For the lysates generated above, 100 Wg was separated on an 8%
SDS^PAGE gel, then transferred to PVDF (2.5 h, 500 mA). Blocking
of membranes and antibody dilutions were performed according to
the manufacturer’s directions. Phospho blots were performed ¢rst;
membranes were then stripped (62.5 mM Tris, pH 6.8, 2% SDS,
and 100 mM L-mercaptoethanol; 55‡C, 30 min), and reprobed for
total protein. Proteins were detected using an enhanced chemilumi-
nescent reagent. Exposure time of the membrane to ¢lm for gastroc
and soleus immunoblots was identical so that direct comparisons of
phospho and total protein could be made between the muscles. Pro-
tein levels were quanti¢ed with the NIH ImageJ densitometry pro-
gram; results are shown as the average density N standard deviation
for three animals, and signi¢cance was determined with a two-sample
t-test.
3. Results
3.1. MAP kinase family member activation during skeletal
muscle atrophy
While JNK activity has been described during conditions of
hypertrophy [18^20], we hypothesized that loss of muscle
mass following extended disuse may also activate this protein
Table 1
Average body weight and muscle masses following a 38-day hind-
limb suspension
Ambulatory Hindlimb suspended
Body mass (g) 254.6N 6.4 251.3N 7.2
Gastrocnemius (g) 1.789N 0.0543 1.383N0.0230
Soleus (g) 0.123N 0.0035 0.050N0.0018
Data are expressed as the mean N standard deviation for 10 ani-
mals.
Fig. 1. The activity MAP kinase family members are elevated in
atrophic muscle. A: GST-c-jun coupled to glutathione Sepharose
beads was used to pulldown JNK from lysates from AMB or HLS
gastroc or soleus muscle. JNK-dependent phosphorylation of GST-
c-jun was assayed from muscle lysates from three di¡erent animals
in duplicate. *P6 0.05 for the di¡erence between HLS and AMB
for gastroc or soleus using two-factor ANOVA with replication.
B^D: Muscle lysates were separated by SDS^PAGE and immuno-
blotted for JNK (panel B), p38 (panel C), and Erk 1/2 (panel D).
In each case, membranes were probed for the activating phosphory-
lation sites (top), then reprobed for total protein (bottom). Proteins
were visualized by enhanced chemiluminescence. Arrows indicate the
alignment of phospho-protein to total protein. Above each lane is
the number used to identify each animal upon the random distribu-
tion into AMB or HLS at the beginning of the study.
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kinase. Exposure of rats to a 38-day hindlimb suspension
regiment resulted in a slight loss in gastroc mass and a
more pronounced loss of soleus mass as summarized in Table
1. Assaying JNK from AMB or HLS rat soleus demonstrated
elevated JNK activity (2.5-fold higher versus control) in the
atrophic soleus (Fig. 1A). To ensure this was speci¢c to atro-
phic, slow-twitch muscle and not a general phenomenon of
atrophied skeletal muscle, JNK activity from gastroc (fast-
twitch) also was measured. Comparison of JNK from AMB
and HLS gastroc muscles showed a much smaller, yet signi¢-
cant increase in activity. Immunoblotting with antibodies di-
rected against the JNK activating phosphorylation sites
(Thr183/Tyr185) also demonstrated that the increase in activity
was much more pronounced in atrophic soleus (Fig. 1B). The
change in activity was not due to expression di¡erences, as no
change was seen in either the 54- or 46-kDa JNK1 and JNK2
protein (Fig. 1B). Comparable results were obtained with
male rats exposed to shorter (21-day) hindlimb suspension
(data not shown).
Similar to JNK, p38 and Erk are activated during short
stints of hypertrophy [33], and p38 activity is elevated follow-
ing a 10-day cast immobilization [34]. In our 38-day hindlimb
suspension, the activities of p38 (Fig. 1C) and Erk 1/2 (Fig.
1D) were both greater in the atrophic soleus as compared to
the control, with the di¡erences not being attributed to altered
expression.
3.2. Serine 307 phosphorylation of IRS-1
JNK has been shown to negatively regulate insulin signaling
through the phosphorylation IRS-1 on Ser307, while prevent-
ing this phosphorylation restores insulin responsiveness in
mice [26]. Using a phospho-speci¢c antibody to Ser307, we
examined the phosphorylation of IRS-1 in AMB and HLS
skeletal muscle. As shown in Fig. 2A, Ser307 phosphorylation
was only detected in HLS soleus; IRS-1 was not phosphory-
lated in the fast-twitch gastroc although JNK activity was
slightly higher in the HLS gastroc versus AMB (Fig. 1). The
increased phosphorylation on Ser307 appears to have caused a
loss in total IRS-1 protein in HLS soleus as compared to the
AMB control (Fig. 2A), whereas IRS-2, shown to be degraded
under some conditions [35], was una¡ected by atrophy (Fig.
2B). Therefore, JNK activity correlated with the Ser307 phos-
phorylation and the degradation of IRS-1 in atrophic soleus
muscle.
3.3. Ser307 phosphorylation of IRS-1 reduces Akt and
GSK-3L activities
Insulin binding to its membrane receptor leads to receptor
tyrosine autophosphorylation, association of IRS-1 with the
receptor, and the recruitment of PI 3-kinase. Since phosphor-
ylation of IRS-1 on Ser307 prevents association with the in-
sulin receptor [23], and IRS-1 protein is lost in atrophic so-
leus, we hypothesized that the coupling of PI 3-kinase to the
insulin receptor would be a¡ected. Using phospho-speci¢c
antibodies to active forms of the kinase, the activities of
Akt (Fig. 3A) and GSK-3L (Fig. 3B), an Akt substrate,
were analyzed. Consistent with the loss of IRS-1 protein, a
speci¢c loss of both Akt and GSK-3L was observed in the
atrophic soleus. While total GSK-3L protein also declined,
Fig. 2. Ser307 phosphorylation of IRS-1 correlates with degradation
of IRS-1 protein. Lysates were immunoblotted for IRS-1 phospho-
serine 307 (pSer307 ; panel A, top), then stripped and reprobed for
total IRS-1 (panel A, bottom); IRS-2 levels were also examined by
immunoblotting (panel B).
Fig. 3. Components of the insulin signaling pathway are reduced
during atrophy. Lysates generated as described in Fig. 1 were im-
munoblotted for Akt (panel A) or GSK-3L (panel B), either for the
activating phosphoserine (top) or for total protein (bottom). Densi-
tometry analysis of phospho-protein relative to total protein is
shown in panel C; results are reported as the average of three
muscles N standard deviation, with *P6 0.05 for the di¡erence be-
tween HLS and AMB for the soleus.
Fig. 4. Insulin receptor expression, but not GLUT4, is reduced in
atrophic soleus muscle. Lysates were immunoblotted for total insu-
lin receptor L-subunit (panel A) or GLUT4 (panel B). Densitometry
analysis of total protein (panel C) is as described in Fig. 3.
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the loss of phospho-GSK-3L was still signi¢cantly lower in
atrophic soleus when compared to AMB muscle (Fig. 3C).
3.4. Insulin receptor-L and GLUT4 alterations in atrophic
muscle
Insulin resistance in skeletal muscle tissue may result from a
loss of the insulin receptor or decreased expression of the
glucose transporters. Therefore, the expression of these pro-
teins was examined from AMB and HLS muscle lysates. In-
terestingly, the L-subunit of the insulin receptor was signi¢-
cantly reduced in atrophic soleus muscle compared to AMB
muscle (Fig. 4A,C). Conversely, the expression of GLUT4,
the insulin-responsive member of the glucose transporter fam-
ily, increased signi¢cantly in atrophic soleus as compared to
control (Fig. 4B,C). Again, these changes were speci¢c to the
slow-twitch soleus, as the atrophic gastroc demonstrated no
signi¢cant change compared to control muscle.
4. Discussion
Serine phosphorylation and the subsequent degradation of
IRS-1 provide one mechanism for insulin resistance. Using a
38-day hindlimb suspension of rats as a model for skeletal
muscle disuse atrophy, we demonstrate increased JNK activity
during atrophy, which corresponds with [34] and contradicts
[36] previous reports. The JNK activity correlates with in-
creased Ser307 phosphorylation of IRS-1, and the correspond-
ing degradation of the protein. Additionally, the activities of
Akt and GSK-3L, enzymes normally activated in response to
insulin, are suppressed in atrophic soleus muscle. Reduced
insulin receptor levels were also found during atrophy, in
agreement with previous studies [37,38], although not to the
same extent as the loss of IRS-1. Interestingly, these ¢ndings
were speci¢c to atrophic slow-twitch muscle, the primary
muscle group a¡ected by disuse and weightlessness [39].
Thus, we propose that the insulin resistance observed during
muscle atrophy is not due to loss of insulin-mediated glucose
transport, as the levels of GLUT4 increase in atrophic muscle.
Although reductions in IRS-1 protein levels were demon-
strated in obese insulin-resistant human skeletal muscle [40]
and chronically insulin-stimulated cultured L6 muscle cells
[41], to our knowledge this study is the ¢rst demonstration
of Ser307 phosphorylation of IRS-1 in atrophic skeletal muscle
tissue.
Current evidence suggests two possible methods for IRS-1
phosphorylation and degradation. JNK has been shown to
associate with and directly phosphorylate IRS-1 in vitro
[23], and cell-permeable JNK inhibitory compounds and pep-
tides, as well as mutations in the IRS-1 JNK-binding domain,
reduce Ser307 phosphorylation [25,27]. Additional evidence
from obese JNK1 knockout mice has shown that these mice
have lower circulating insulin and glucose and Ser307 phos-
phorylation when compared to obese JNK1þ=þ mice [26].
However, JNK-independent phosphorylation of IRS-1 has
also been described. Chronic insulin stimulation of a number
of cell types in culture has shown that the phosphorylation
and degradation of IRS-1 can be prevented by pretreatment
of cells with wortmannin or rapamycin, suggesting that the PI
3-kinase/Akt/mTOR pathway is responsible [30,42^44]. Taken
together, these JNK-dependent and -independent results sug-
gest that chronic insulin stimulation of PI 3-kinase/Akt/
mTOR and cell stress-induced JNK activation may be distinct
signals that result in IRS-1 serine phosphorylation, degrada-
tion, and insulin resistance.
Our results favor the JNK-dependent phosphorylation of
IRS-1 for a number of reasons. First, decreased protein syn-
thesis is prominent in muscle atrophy, partially due to reduced
p70 S6-kinase activity [3]. The activities of mTOR and p70 S6-
kinase are intimately linked, suggesting the mTOR-dependent
activity is not responsible for IRS-1 serine phosphorylation.
Second, the loss of insulin receptor numbers during atrophy
(Fig. 4A and [37,38]), combined with the reduction in Akt
activity (Fig. 3A), suggests the overstimulation of the PI
3-kinase/Akt/mTOR pathway is not signi¢cantly contributing
to IRS-1 serine phosphorylation and degradation. Third, hu-
man muscle atrophy studies with the head-down bed rest
model have demonstrated that there are no changes in circu-
lating insulin-like growth factor-I (IGF-I) or insulin [45]. To-
gether, these data suggest that chronic receptor stimulation
does not contribute to IRS-1 serine phosphorylation and in-
sulin resistance. Rather, our data are consistent with a model
of cell stress-induced JNK activity contributing to the devel-
opment of insulin resistance in muscle atrophy.
Moreover, Erk and p38 both contribute to glucose uptake.
High extracellular glucose and exercise have been shown to
activate Erk, which in turn, through the activation of atypical
PKCs, stimulates glucose uptake independent of insulin [46].
p38 is hypothesized to be an activator of GLUT4, as inhib-
itors of p38 do not prevent the translocation of GLUT4 to the
membrane but block insulin-stimulated glucose transport
[47,48]. The fact that Erk and p38 activities are elevated in
atrophic skeletal muscle is intriguing in that they provide a
mechanism to explain how glucose uptake can occur in the
absence of insulin signaling through IRS-1 in atrophic muscle.
While atrophic, slow-twitch muscle prefers carbohydrates as a
fuel source, it appears that the inherent activation of the stress
kinases during atrophy ^ JNK to degrade IRS-1 and Erk/p38
to enhance glucose uptake ^ may be two competing signals
that maintain glucose uptake. Further studies will be needed
to clarify the role of these MAP kinases throughout the pro-
gression of skeletal muscle atrophy.
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